Blue flexible cystoscopy used in an office-setting can improve detection of bladder cancer recurrence, according to the findings of a phase 3 study presented at the 2017 American Urological Association annual meeting in Boston, by Siamak Daneshmand, MD, of the Keck School of Medicine at Southern California University in Los Angeles.
In the study, which included 304 patients at 17 academic institutions in the United States, 21.5% of recurrences were seen with blue light cystoscopy only. More than 90% of patients said the blue light flexible cystoscopy was a worthwhile procedure and would undergo it again. “This is important because there is an extra step to the procedure with the instillation of the agent [hexaminolevulinate HCl] into the bladder,” Dr. Daneshmand said.
Enjoying our content?
Thanks for visiting Renal & Urology News. We hope you’re enjoying the latest clinical news, full-length features, case studies, and more.
You’ve viewed {{metering-count}} of {{metering-total}} articles this month. If you wish to read unlimited content, please log in or register below. Registration is free.
{{login-button}} {{register-button}}
Log in to continue reading this article.
Don’t miss out on today’s top content on Renal & Urology News. Register for free and gain unlimited access to:
- Clinical News, with personalized daily picks for you
- Case Studies
- Conference Coverage
- Full-Length Features
- Drug Monographs
- And More
{{login-button}} {{register-button}}
Want to read more?
Please login or register first to view this content.